Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses

Li, Xin; Meng, Xiangxi; Wang, Shengnan; Li, Zhiqin; Yang, Lei; Tu, Liqun; Diao, Wenzhen; Yu, Chih-Chia; Yu, Yongli; Yan, Chaoying; Wang, Liying

doi:10.1007/s00253-018-9361-2

Cited by 17 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stenfeld et al ( 52 ) demonstrated the role of a CTL response in preventing the FMDV carrier state in vaccinated cattle. Besides, the percentage of CD4+ lymphocytes and the CD4/CD8 ratio after vaccination may serve as a parameter to select young sires with a high immune response against FMDV ( 53 ). Moreover, IFN-γ displays activity against FMDV ( 54 ), by controlling viral replication and spreading within the host through natural killer cell and macrophage activation ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

et al. 2020

View full text Add to dashboard Cite

Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important economy losses. Vaccines with new low-cost adjuvants that stimulate protective immune responses are needed and can be assayed in a mouse model to predict their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine, cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus, in the present work, we studied the effects on the magnitude and type of immunity elicited in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV) formulated with ISPA. It was demonstrated that iFMDV-ISPA induced protection in mice against challenge and elicited a specific antibody response in sera, characterized by a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an expected percentage of protection (EPP) higher than 80%. EPP calculates the probability that livestock would be protected against a 10,000 bovine infectious doses challenge after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine, iFMDV-ISPA elicited an increased specific T-cell response against the virus, including higher interferon gamma (IFNγ)+/CD8+ lymphocyte production in cattle. In this work, we report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is capable of inducing protection against challenge in a murine model and of improving the specific immune responses against the virus in cattle.

show abstract

Section: Discussionmentioning

confidence: 99%

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In 2011, the Hecoin vaccine for hepatitis E virus (HEV) that was developed by Innovax Biotech of Xiamen, China, was approved for use in China. In the veterinary field, a vaccine for porcine circovirus type 2 (PCV-2) developed using VLPs has been approved for marketing (Intervet International Ltd., the Netherlands) (17). VLPs can effectively activate APCs and B lymphocytes by virtue of their size, potential and other properties (18,19).…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB/c Mice

Han

Zhao

et al. 2020

Front. Vet. Sci.

View full text Add to dashboard Cite

Rift Valley fever (RVF) is an acute, febrile zoonotic disease that is caused by the RVF virus (RVFV) and is spread by arthropod vectors. Virus-like particle (VLP) vaccines, which have the advantages of strong immunogenicity and safety, play an important role in the prevention of this disease. VLPs for RVFV were successfully prepared by our research group using a baculovirus-insect cell expression system. To study the immunogenicity of these RVFV VLPs, a correct 3rd or 4th generation recombinant baculovirus, rBac-N-G, was identified and used to infect Sf9 cells, which were cultured in suspension at a large scale. Subsequently, cell debris was removed by centrifugation, and the VLPs were concentrated by ultracentrifugation and purified using a sucrose gradient, after which they were used to immunize BALB/c mice by intramuscular injection. The results showed that the RVFV VLPs prepared by our research group could effectively induce mice to produce RVFV neutralizing antibodies and that the prepared VLPs could stimulate mouse spleen cells to produce high levels of the cytokines IL-4 and IFN-γ. Moreover, the proportion of lymphocytes producing IL-4 and IFN-γ in the spleen of mice immunized with RVFV VLPs was significantly increased. Therefore, the RVFV VLPs prepared in this study had strong immunogenicity and could effectively activate humoral and cellular immunity in mice. This study lays a solid foundation for the development of RVFV VLP vaccine candidates and promotes the healthy development of animal husbandry and human public health.

show abstract

“…More recently, experimental vaccines based on the chimeric viruses PCV1 and PCV2 were formulated in chimeric porcine circovirus-Cap proteins, where small Cap loops were replaced with other epitopes of interest. These chimeric proteins were expressed in Escherichia coli (E. coli), preserving the structure of the VLP [30][31][32], and this approach was demonstrated as an alternative against PCV2 infection.…”

Section: Introductionmentioning

confidence: 99%

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

Lamazares

Gutiérrez

Hidalgo

et al. 2020

Viruses

View full text Add to dashboard Cite

Recombinant vaccines have low-cost manufacturing, regulatory requirements, and reduced side effects compared to attenuated or inactivated vaccines. In the porcine industry, post-weaning multisystemic disease syndrome generates economic losses, characterized by progressive weight loss and weakness in piglets, and it is caused by porcine circovirus type 2 (PCV2). We designed a chimeric antigen (Qm1) to assemble the main exposed epitopes of the Cap-PCV2 protein on the capsid protein of the tobacco necrosis virus (TNV). This design was based on the Cap-N-terminal of an isolated PCV2 virus obtained in Chile. The virus was characterized, and the sequence was clustered within the PCV2 genotype b clade. This chimeric protein was expressed as inclusion bodies in both monomeric and multimeric forms, suggesting a high-molecular-weight aggregate formation. Pigs immunized with Qm1 elicited a strong and specific antibody response, which reduced the viral loads after the PCV2 challenge. In conclusion, the implemented design allowed for the generation of an effective vaccine candidate. Our proposal could be used to express the domains or fragments of antigenic proteins, whose structural complexity does not allow for low-cost production in Escherichia coli. Hence, other antigen domains could be integrated into the TNV backbone for suitable antigenicity and immunogenicity. This work represents new biotechnological strategies, with a reduction in the costs associated with vaccine development.

show abstract

Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses

Cited by 17 publications

References 30 publications

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB/c Mice

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

Contact Info

Product

Resources

About